Marc Rendell

Nia Association — United States

Medicine · Health Sciences

50h-index9.9kcitations254works0.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Diabetes Management and Research(78), Diabetes Treatment and Management(74), Pancreatic function and diabetes(44), Metabolism, Diabetes, and Cancer(39), Diabetes and associated disorders(30)

Publications244 total

Review for "Hepatic GCGR is required for the superior weight loss and metabolic effects of a structurally related analogue of the dual GCGR/GLP-1R agonist survodutide in mice"
2025
Review for "Use of sodium-glucose cotransporter-2 inhibitors among older adults with type 2 diabetes mellitus in British Columbia"
2025
Review for "Hepatic GCGR is required for the superior weight loss and metabolic effects of a structurally related analogue of the dual GCGR/GLP-1R agonist survodutide in mice"
2025
Review for "Practical limitations of complex insulin therapies in type 2 diabetes: Focus on therapy simplification using fixed‐ratio combinations of basal insulin and a glucagon‐like peptide‐1 receptor agonist"
2025
Review for "Practical limitations of complex insulin therapies in type 2 diabetes: Focus on therapy simplification using fixed‐ratio combinations of basal insulin and a glucagon‐like peptide‐1 receptor agonist"
2025
Pharmacotherapy of type 1 diabetes - part 2 Today
Expert Opinion on Pharmacotherapy·2025
Pharmacotherapy of type 1 diabetes – part 3: tomorrow
Expert Opinion on Pharmacotherapy·2025
Pharmacotherapy of type 1 diabetes - part 1: yesterday
Expert Opinion on Pharmacotherapy·2025
Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label study
Diabetes Obesity and Metabolism·2024· 3 cited
Lessons learned from early-stage clinical trials for diabetic nephropathy
Expert Opinion on Investigational Drugs·2024
Author response for "Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label study"
2024
Review for "A phase 1, randomized, double‐blind, placebo‐controlled trial investigating the pharmacokinetics, pharmacodynamics, safety and tolerability of oral semaglutide in healthy Chinese subjects"
2024
Author response for "Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label study"
2024
An Independent Analysis of a Retrospective Cohort of 30,423 Covid-19 Patients Treated at IHU-Mediterranean in Marseille, France: Part 1, Efficacy of early Treatment with Hydroxychloroquine and Azithromycin
Archives of Microbiology & Immunology·2024Open Access
An Independent Analysis of a Retrospective Cohort of 30,423 Covid-19 Patients Treated at IHU-Mediterranean in Marseille, France: Part 2, a Real-life Assessment of Covid-19 Vaccination Efficacy
Archives of Microbiology & Immunology·2024Open Access
Review for "A phase 1, randomized, double‐blind, placebo‐controlled trial investigating the pharmacokinetics, pharmacodynamics, safety and tolerability of oral semaglutide in healthy Chinese subjects"
2023
Major Update: Masks for Prevention of SARS-CoV-2 in Health Care and Community Settings
Annals of Internal Medicine·2023
Review for "The real‐world observational prospective study of health outcomes with dulaglutide and liraglutide in patients with type 2 diabetes (<scp>TROPHIES</scp>): Final, 24‐month analysis of time to first significant treatment change, treatment persistence and clinical outcomes"
2023
Review of: "Tocilizumab Plus Corticosteroid in Elderly Patients Hospitalized With COVID-19 Pneumonia: A Retrospective Cohort Study"
2023Open Access
Review of: "A Villain in Disguise in the Management of Painful Peripheral Neuropathy: A Case Report"
2023Open Access
page 1 of 13Next →

Frequent Co-authors

Yoram Salomon(5), Martin Rodbell(5), Philip Raskin(3), Simeón Margolis(3), Julio Rosenstock(3), Ming‐Chih Lin(3), Constantine Londos(3), Binh Ngo(3), Jefferson J. Katims(3), Ingrid Mattiasson(3), U. Lennart Hulthén(3), Daniel Einhorn(2), John Egan(2), Annette Mathisen(2), Roberta L Schneider(2), Stuart C. Apfel(2), Jo Dole(2), Martin I. Freed(2), Mark Rigby(2), Ashley Pinckney(2)